Central Trust Company’s Novavax NVAX Stock Holding History

Central Trust Company’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-20	Closed	-$129	–	1471
2025 Q1	$129	Buy	+20	New	+$165	﹤0.01%	1430
2024 Q2	–	Sell	-106	Closed	-$507	–	1439
2024 Q1	$507	Buy	106 +6	+6%	+$28	﹤0.01%	1346
2023 Q4	$480	Hold	100	–	–	﹤0.01%	1353
2023 Q3	$724	Hold	100	–	–	﹤0.01%	1325
2023 Q2	$743	Hold	100	–	–	﹤0.01%	1207
2023 Q1	$693	Hold	100	–	–	﹤0.01%	1236
2022 Q4	$1.03K	Hold	100	–	–	﹤0.01%	1196
2022 Q3	$2K	Hold	100	–	–	﹤0.01%	1211
2022 Q2	$5K	Hold	100	–	–	﹤0.01%	1128
2022 Q1	$7K	Sell	100 -34	-25%	-$3.03K	﹤0.01%	1123
2021 Q4	$19K	Hold	134	–	–	﹤0.01%	958
2021 Q3	$28K	Hold	134	–	–	﹤0.01%	858
2021 Q2	$28K	Buy	134 +34	+34%	+$6.23K	﹤0.01%	825
2021 Q1	$18K	Hold	100	–	–	﹤0.01%	852
2020 Q4	$11K	Hold	100	–	–	﹤0.01%	889
2020 Q3	$11K	Buy	+100	New	+$12.2K	﹤0.01%	850

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Central Trust Company's NVAX Position: Q2 2025 in Review

Central Trust Company sold out of Novavax (NVAX) in Q2 2025, closing a stake of 20 shares — an estimated $129 sold.

Central Trust Company first reported a position in NVAX in Q3 2020 and held it in 16 quarters. The position peaked at $28K in Q3 2021. 250 funds tracked by Wall St. Rank hold NVAX as of Q2 2025.

Central Trust Company reported no remaining Novavax position as of Q2 2025 after selling out during the quarter.
Central Trust Company sold 20 Novavax shares in Q2 2025, an estimated $129.
Central Trust Company first reported a position in Novavax in Q3 2020 and held it in 16 quarters.
Central Trust Company's Novavax position peaked at $28K in Q3 2021.
250 funds tracked by Wall St. Rank held Novavax as of Q2 2025.

Based on Central Trust Company's 13F filing for Q2 2025, filed 7 Aug 2025.